Patents Assigned to The Rockefeller University
  • Patent number: 8101821
    Abstract: The present invention relates to methods for promoting somatic embryogenesis from a tissue or organ of a plant, by overexpressing a Wuschel gene in said tissue or organ. In one embodiment, such overexpression can be used as a silent selectable marker for transgenic plants. In another embodiment, such expression can be used to confer apomixis to a plant. In another embodiment, such overexpression can be used to create haploid plants, which can be used to produce dihaploid plants.
    Type: Grant
    Filed: June 21, 2011
    Date of Patent: January 24, 2012
    Assignee: The Rockefeller University
    Inventors: Jianru Zuo, Qi-Wen Niu, Giovanna Frugis, Nam-Hai Chua
  • Patent number: 8088914
    Abstract: The invention relates to isolated DNA or RNA molecules comprising at least ten contiguous bases having a sequence in a pancreatic islet microRNA. In another embodiment, the invention relates to isolated single stranded pancreatic islet microRNA molecules or anti-pancreatic islet microRNA molecules.
    Type: Grant
    Filed: July 6, 2009
    Date of Patent: January 3, 2012
    Assignee: The Rockefeller University
    Inventors: Markus Stoffel, Matthew N. Poy, Thomas H. Tuschl
  • Patent number: 8088902
    Abstract: The invention relates to isolated nucleic acid molecules comprising the sequence of a human cytomegalovirus microRNA. In another embodiment, the invention relates to single stranded DNA virus microRNA molecules comprising the sequence of a human cytomegalovirus microRNA. The invention also relates to the anti-DNA virus microRNA molecules.
    Type: Grant
    Filed: October 19, 2004
    Date of Patent: January 3, 2012
    Assignee: The Rockefeller University
    Inventors: Sebastien Pfeffer, Thomas Tuschl
  • Patent number: 8067156
    Abstract: Sequences are provided that are capable of directing circular adeno-associated virus replication, useful in vectors for providing therapeutic agents to a subject in need thereof. The vectors of the invention are particularly useful in the treatment of acute medical conditions requiring rapid gene expression. Further provided are methods for producing packaged defective viral vectors.
    Type: Grant
    Filed: May 31, 2002
    Date of Patent: November 29, 2011
    Assignee: The Rockefeller University
    Inventors: Michael G. Kaplitt, Sergei Moussatov
  • Patent number: 8049814
    Abstract: The preferred embodiments of the present invention include a holography attachment device that is attachable to a digital imaging device to form a holographic microscope. The holography attachment device includes a chamber having at least one attachment mechanism to facilitate attachment of the chamber to a digital imaging device. The holography attachment device also includes a light source and a sample holder section, which is located between a proximate end and the distal end of the chamber. The light source is configured to radiate light within the chamber. The light passes through the sample holder section and impinges on an imaging sensor of a digital imaging device when the chamber is attached to the digital imaging device. The digital imaging device is capable of recording hologram information related to a sample held by the sample holder in the sample holder section.
    Type: Grant
    Filed: March 27, 2008
    Date of Patent: November 1, 2011
    Assignee: The Rockefeller University
    Inventors: Stanislas Leibler, Seppe Kuehn, Zak Frentz, Doeke Hekstra
  • Publication number: 20110263495
    Abstract: The present invention is directed to methods of treating Type I diabetes by administering a therapeutically effective amount of an Insulin-like Growth Factor-binding protein-2. The present invention is also directed to methods treating Type 2 diabetes comprising the step of administering a therapeutically effective amount of Insulin-like Growth Factor-binding protein-2. The present invention is further directed to methods treating insulin resistance comprising the step of administering a therapeutically effective amount of Insulin-like Growth Factor-binding protein-2. The present invention is directed to methods of treating hepatic steatosis by administering a therapeutically effective amount of an Insulin-like Growth Factor-binding protein-2. The present invention is also directed to methods lowering blood glucose and serum insulin in non-diabetic subjects comprising the step of administering a therapeutically effective amount of Insulin-like Growth Factor-binding protein-2.
    Type: Application
    Filed: October 29, 2009
    Publication date: October 27, 2011
    Applicant: The Rockefeller University
    Inventors: Jeffrey Friedman, Kristina Hedbacker
  • Patent number: 8030029
    Abstract: This disclosure is directed, inter alia, to polynucleotides, polypeptides, vectors, cells and compositions comprising the same, and their use in affecting viral pathogenesis, in particular for influenza viral infection.
    Type: Grant
    Filed: January 23, 2008
    Date of Patent: October 4, 2011
    Assignees: Academia Sinica, The Rockefeller University
    Inventors: David D. Ho, Yaoxing Huang, Ming Wei Chen, Rachel TJ Cheng, Chi-Huey Wong, Alice Yu
  • Patent number: 8021838
    Abstract: The present invention describes a method of identifying inducible genetic regulatory sequences that can control the transcription of specific gene transcripts. Methods of using inducible genetic regulatory sequences are also discussed. In particular, the genetic regulatory sequences of the present invention can modulate the transcription of a nucleic acid transcript in vivo.
    Type: Grant
    Filed: October 3, 2006
    Date of Patent: September 20, 2011
    Assignees: The Rockefeller University, Thomas Jefferson University, Neurologix Research, Inc.
    Inventors: Michael G. Kaplitt, Matthew J. During, Andres M. Lozano
  • Patent number: 8021835
    Abstract: The invention relates to the discovery that the Claudin-1 protein functions as a co-receptor for entry of HCV into cells. Methods of inhibiting, preventing or mitigating HCV infections by inhibiting HCV interactions with Claudin-1 are provided. Methods of identifying agents or compounds that interfere with HCV interactions with Claudin-1 are also provided. Finally, useful kits, cell culture compositions, agents, and compounds related to the inhibition of HCV interactions with Claudin-1 are also disclosed.
    Type: Grant
    Filed: May 4, 2007
    Date of Patent: September 20, 2011
    Assignee: The Rockefeller University
    Inventors: Charles Rice, Matthew J. Evans, Thomas Von Hahn
  • Patent number: 8013118
    Abstract: The present invention provides a novel family of polypeptides which are ligand-gated channel receptor accessory molecules or ligands, denoted Lynx. This invention provides an isolated polypeptide comprising an amino acid sequence of a Lynx polypeptide in which the amino acid sequence is set forth in SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO:15, including fragments, mutants, variants, analogs, homologs, or derivatives of the amino acid sequences set forth in SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO:15. This invention further provides an isolated immunogenic polypeptide; an isolated nucleic acid; pharmaceutical compositions and diagnostic and therapeutic methods of use of the isolated polypeptides and nucleic acids of the present invention; assays for compounds which mimic, alter or inactivate the polypeptides of the present invention for use in therapy; and methods of isolating Lynx polypeptides and the nucleic acids encoding such polypeptides.
    Type: Grant
    Filed: December 18, 2002
    Date of Patent: September 6, 2011
    Assignee: The Rockefeller University
    Inventors: Nathaniel Heintz, Julie M. Miwa, Ines Ibanez-Tallon
  • Patent number: 7994301
    Abstract: Modulators of weight, including, for example, two isoforms of murine and human ob polypeptides, are provided, as well as diagnostic and therapeutic uses and methods comprising such. Also provided are nucleotide sequences, degenerate variations thereof, and proteins expressed by such.
    Type: Grant
    Filed: April 21, 2009
    Date of Patent: August 9, 2011
    Assignee: The Rockefeller University
    Inventors: Jeffrey M. Friedman, Yiying Zhang, Ricardo Proenca
  • Patent number: 7989203
    Abstract: This invention relates to methods and compositions useful for delivering antigens to dendritic cells which are then useful for inducing antigen-specific cytotoxic T lymphocytes and T helper cells. This invention also provides assays for evaluating the activity of cytotoxic T lymphocytes. According to the invention, antigens are targeted to dendritic cells by apoptotic cells which may also be modified to express non-native antigens for presentation to the dendritic cells. The dendritic cells which are primed by the apoptotic cells are capable of processing and presenting the processed antigen and inducing cytotoxic T lymphocyte activity or may also be used in vaccine therapies.
    Type: Grant
    Filed: June 9, 2006
    Date of Patent: August 2, 2011
    Assignee: The Rockefeller University
    Inventors: Matthew L. Albert, Nina Bhardwaj, Ralph M. Steinman, Kayo Inaba, Robert Darnell
  • Patent number: 7981428
    Abstract: This disclosure is directed, inter alia, to polynucleotides, polypeptides, vectors, cells and compositions comprising the same, and their use in affecting viral pathogenesis, in particular for influenza viral infection.
    Type: Grant
    Filed: April 2, 2009
    Date of Patent: July 19, 2011
    Assignees: Academia Sinica, The Rockefeller University
    Inventors: Chi-Huey Wong, David D. Ho, Yaoxing Huang, Ting-Jen R. Cheng, Ming Wei Chen, Alice Yu
  • Patent number: 7977534
    Abstract: The present invention relates to methods for promoting somatic embryogenesis from a tissue or organ of a plant, by overexpressing a Wuschel gene in said tissue or organ. In one embodiment, such overexpression can be used as a silent selectable marker for transgenic plants. In another embodiment, such expression can be used to confer apomixis to a plant. In another embodiment, such overexpression can be used to create haploid plants, which can be used to produce dihaploid plants.
    Type: Grant
    Filed: September 23, 2010
    Date of Patent: July 12, 2011
    Assignee: The Rockefeller University
    Inventors: Jianru Zuo, Qi-Wen Niu, Giovanna Frugis, Nam-Hai Chua
  • Patent number: 7968299
    Abstract: The present invention is method of determining whether or not associations between a given protein and other proteins in a cell are specific.
    Type: Grant
    Filed: August 21, 2006
    Date of Patent: June 28, 2011
    Assignee: The Rockefeller University
    Inventors: Brian T. Chait, Alan J. Tackett, Jeffrey A. DeGrasse, Marlene Oeffinger, Michael P. Rout, Matthew D. Sekedat
  • Patent number: 7951453
    Abstract: The invention provides a water soluble complex comprising an inner core of a metal or semi-conductor nanoparticle. The nanoparticle is coated with a hydrophobic ligand, which is encapsulated in a micelle. In an aqueous medium, the micelle comprises a hydrophilic shell and a hydrophobic core, the hydrophilic shell comprising a plurality of hydrophilic moieties, the hydrophobic core comprising a plurality of hydrophobic moieties, each hydrophobic moiety comprising at least one chain, each chain comprising a minimum of 8 atoms; wherein the total number of atoms in all chains for each moiety comprises at least 24 atoms. The micelle has a minimum average diameter of approximately 5 nm and a maximum average diameter of approximately 45 nm.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: May 31, 2011
    Assignee: The Rockefeller University
    Inventors: Benoit Dubertret, Vincent Noireaux, Albert Libchaber
  • Patent number: 7939170
    Abstract: The invention provides a water soluble complex comprising an inner core of a metal or semi-conductor nanoparticle. The nanoparticle is coated with a hydrophobic ligand, which is encapsulated in a micelle. In an aqueous medium, the micelle comprises a hydrophilic shell and a hydrophobic core, the hydrophilic shell comprising a plurality of hydrophilic moieties, the hydrophobic core comprising a plurality of hydrophobic moieties, each hydrophobic moiety comprising at least one chain, each chain comprising a minimum of 8 atoms; wherein the total number of atoms in all chains for each moiety comprises at least 24 atoms. The micelle has a minimum average diameter of approximately 5 nm and a maximum average diameter of approximately 45 nm.
    Type: Grant
    Filed: August 15, 2002
    Date of Patent: May 10, 2011
    Assignee: The Rockefeller University
    Inventors: Benoit Dubertret, Vincent Noireaux, Albert Libchaber
  • Patent number: 7923013
    Abstract: This invention relates to immunogenic compounds which serve as ligands for NKT (natural killer T) cells and to methods of use thereof in modulating immune responses.
    Type: Grant
    Filed: April 13, 2007
    Date of Patent: April 12, 2011
    Assignees: The Rockefeller University, The Scripps Research Institute
    Inventors: Moriya Tsuji, David D. Ho, Chi-Huey Wong, Douglass Wu, Masakazu Fujio, Xiangming Li
  • Patent number: 7923247
    Abstract: A method for producing proliferating cultures of dendritic cell precursors is provided. Also provided is a method for producing mature dendritic cells in culture from the proliferating dendritic cell precursors. The cultures of mature dendritic cells provide an effective means of producing novel T cell dependent antigens comprised of dendritic cell modified antigens or dendritic cells pulsed with antigen, including particulates, which antigen is processed and expressed on the antigen-activated dendritic cell. The novel antigens of the invention may be used as immunogens for vaccines or for the treatment of disease. These antigens may also be used to treat autoimmune diseases such as juvenile diabetes and multiple sclerosis.
    Type: Grant
    Filed: July 17, 2008
    Date of Patent: April 12, 2011
    Assignees: Argos Therapeutics, Inc., The Rockefeller University
    Inventors: Ralph M. Steinman, Kayo Inaba, Gerold Schuler
  • Publication number: 20110076277
    Abstract: A mammalian C-type lectin receptor type is identified which is shown to bind IgG antibodies or Fc fragments, thus inducing IVIG-related reversal of inflammation associated with various immune disorders. The identification of a DC-SIGN receptor type which interacts with IgG to promote a biological response reducing inflammation associated with immune disorders provides for methods of screening and selecting compounds which may be useful in treating various immune disorders by acting to modulate a DC-SIGN(+) cell to signal a second effector macrophage, causing an increase in expression of the Fc?RIIB receptor and in turn inhibiting a cellular-mediated inflammatory response.
    Type: Application
    Filed: November 19, 2010
    Publication date: March 31, 2011
    Applicant: The Rockefeller University
    Inventors: Jeffrey V. Ravetch, Robert Anthony